EDQM Launches Counterfeit Drug Database - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EDQM Launches Counterfeit Drug Database


The European Directorate for the Quality of Medicines & HealthCare (EDQM) announced the launch of a new database, Know-X, which collates reports on counterfeit/falsified medical products that have been detected in Council of Europe member states.

The user-friendly tool was developed to assist officials by expanding knowledge and awareness of the problem of counterfeit/falsified medicines, provide a basis for the exchange of information, highlight and encourage collaboration between health and law enforcement authorities, and foster the sharing of analytical information on the testing of counterfeit/falsified and other illegal medicines within the Network of Official Medicines Control Laboratories (OMCLs), EDQM reports in a statement.

The database contains details on closed cases of counterfeit/falsified medical products, technical information on the testing performed, the authorities involved and what actions were taken. The information provided is gathered from OMCLs, health authorities, regulatory agencies, medical products surveillance authorities, customs, and police and is intended to provide governments with decision aids for the management and prevention of specific risks.

Access can be requested by officials working for a competent health or law enforcement authority in a Council of Europe member state or in a state party to the MEDICRIME Convention that is directly involved in fighting counterfeit/falsified medical products and similar crimes, or a member of the European OMCL Network that does not belong to the core testing group.

Source: EDQM

 

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications

Click here